Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947248367> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2947248367 endingPage "6041" @default.
- W2947248367 startingPage "6041" @default.
- W2947248367 abstract "6041 Background: The capacity for radiation and checkpoint inhibitors to elicit clinical responses is impacted by tumor immunogenicity and the immune microenvironment. We sought to determine whether head and neck primary site and metastatic tumor location was associated with initial response in non-irradiated lesions. Methods: We evaluated response in 144 non-irradiated lesions from 59 patients with metastatic head and neck cancer enrolled on a phase II randomized controlled trial of nivolumab with stereotactic body radiotherapy (n=30) vs. nivolumab alone (n=29). Nivolumab was administered 3 mg/kg intravenously every 2 weeks. Radiated lesions were treated with 27 Gy / 3 fractions to a single lesion within 14 days of the first dose of nivolumab. Non-target lesion progression was defined ≥30% increase in the greatest axial diameter 8 weeks after enrollment. Fisher’s exact test with nested bootstrap resampling was used for univariate analysis. Logistic regression with a mixed random effects term was used for multivariate analysis. Results: Primary tumor site, metastatic tumor organ sites, and the unadjusted likelihood of progressive disease by site are listed in the table. On multivariate logistic regression controlling for PD-L1 status (p=0.66) and viral status (p=0.29), lymph node metastases (OR 0.79, p=0.0064) were associated with decreased risk of progression, while liver metastases (OR 1.39, p=0.014) and oral cavity primaries (OR 1.56, p=0.018) were associated with increased risk of progression at 8 weeks, using lung metastases and larynx/hypopharynx primaries as reference. Conclusions: Primary tumor subsite and metastasis location were predictors of response or stable disease following treatment with nivolumab. Metastases from oral cavity primaries and metastases to the liver were at increased risk of early progression. Clinical trial information: NCT02684253. [Table: see text]" @default.
- W2947248367 created "2019-06-07" @default.
- W2947248367 creator A5012145979 @default.
- W2947248367 creator A5018801529 @default.
- W2947248367 creator A5027048828 @default.
- W2947248367 creator A5033079800 @default.
- W2947248367 creator A5052610122 @default.
- W2947248367 creator A5061365371 @default.
- W2947248367 creator A5079162702 @default.
- W2947248367 creator A5088797923 @default.
- W2947248367 date "2019-05-20" @default.
- W2947248367 modified "2023-10-12" @default.
- W2947248367 title "Predictors of early immunotherapy response in head and neck cancer: Per lesion analysis of a prospective randomized trial with nivolumab." @default.
- W2947248367 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.6041" @default.
- W2947248367 hasPublicationYear "2019" @default.
- W2947248367 type Work @default.
- W2947248367 sameAs 2947248367 @default.
- W2947248367 citedByCount "2" @default.
- W2947248367 countsByYear W29472483672020 @default.
- W2947248367 crossrefType "journal-article" @default.
- W2947248367 hasAuthorship W2947248367A5012145979 @default.
- W2947248367 hasAuthorship W2947248367A5018801529 @default.
- W2947248367 hasAuthorship W2947248367A5027048828 @default.
- W2947248367 hasAuthorship W2947248367A5033079800 @default.
- W2947248367 hasAuthorship W2947248367A5052610122 @default.
- W2947248367 hasAuthorship W2947248367A5061365371 @default.
- W2947248367 hasAuthorship W2947248367A5079162702 @default.
- W2947248367 hasAuthorship W2947248367A5088797923 @default.
- W2947248367 hasConcept C121608353 @default.
- W2947248367 hasConcept C126322002 @default.
- W2947248367 hasConcept C143998085 @default.
- W2947248367 hasConcept C2776530083 @default.
- W2947248367 hasConcept C2777701055 @default.
- W2947248367 hasConcept C2779013556 @default.
- W2947248367 hasConcept C2780030458 @default.
- W2947248367 hasConcept C2780283643 @default.
- W2947248367 hasConcept C2781274730 @default.
- W2947248367 hasConcept C71924100 @default.
- W2947248367 hasConceptScore W2947248367C121608353 @default.
- W2947248367 hasConceptScore W2947248367C126322002 @default.
- W2947248367 hasConceptScore W2947248367C143998085 @default.
- W2947248367 hasConceptScore W2947248367C2776530083 @default.
- W2947248367 hasConceptScore W2947248367C2777701055 @default.
- W2947248367 hasConceptScore W2947248367C2779013556 @default.
- W2947248367 hasConceptScore W2947248367C2780030458 @default.
- W2947248367 hasConceptScore W2947248367C2780283643 @default.
- W2947248367 hasConceptScore W2947248367C2781274730 @default.
- W2947248367 hasConceptScore W2947248367C71924100 @default.
- W2947248367 hasIssue "15_suppl" @default.
- W2947248367 hasLocation W29472483671 @default.
- W2947248367 hasOpenAccess W2947248367 @default.
- W2947248367 hasPrimaryLocation W29472483671 @default.
- W2947248367 hasRelatedWork W2055887390 @default.
- W2947248367 hasRelatedWork W2076245797 @default.
- W2947248367 hasRelatedWork W2079678666 @default.
- W2947248367 hasRelatedWork W2206223252 @default.
- W2947248367 hasRelatedWork W2408995019 @default.
- W2947248367 hasRelatedWork W2418774573 @default.
- W2947248367 hasRelatedWork W2553255798 @default.
- W2947248367 hasRelatedWork W3204410626 @default.
- W2947248367 hasRelatedWork W367573814 @default.
- W2947248367 hasRelatedWork W4223629512 @default.
- W2947248367 hasVolume "37" @default.
- W2947248367 isParatext "false" @default.
- W2947248367 isRetracted "false" @default.
- W2947248367 magId "2947248367" @default.
- W2947248367 workType "article" @default.